JenaValve appoints medtech veteran Drachman CEO
This article was originally published in Clinica
German transcatheter aortic valve developer JenaValve has made David Drachman CEO, replacing Helmut Straubinger, who has headed up the company since 2006. Mr Drachman, who JenaValve hopes will help position it as “a significant player in the TAVI space,” has 30 years of experience in the cardiovascular medical device industry. Most recently, he was president and CEO of atrial fibrillation treatment specialist AtriCure from 2002 until September 2012. Before this, he was at Biosense Webster, which has since become part of Johnson & Johnson; and previously led Impulse Dynamics. Mr Drachman has also worked for Ventritex and Boston Scientific.